Zorevunersen (STK-001)
Dravet Syndrome
Phase 3Ongoing clinical studies; Phase 3 study now underway
Key Facts
Indication
Dravet Syndrome
Phase
Phase 3
Status
Ongoing clinical studies; Phase 3 study now underway
Company
About Stoke Therapeutics
Stoke Therapeutics is developing first-in-class RNA medicines designed to address the underlying genetic causes of severe diseases by restoring protein expression. The company's core TANGO (Targeted Augmentation of Nuclear Gene Output) platform represents a distinct approach in RNA therapeutics, targeting haploinsufficiencies. With its lead program in Phase 3 for Dravet syndrome and promising preclinical data in autosomal dominant optic atrophy (ADOA), Stoke is positioned to potentially deliver disease-modifying therapies. The company is publicly traded and is advancing a pipeline focused on severe genetic disorders of the central nervous system and eye.
View full company profileTherapeutic Areas
Other Dravet Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed PRAM (SCN1A-targeting) | CAMP4 Therapeutics | Preclinical |